N-methyl-D-aspartate receptor glycine co-agonist site (NMDA receptor glycine site)

The **N-methyl-D-aspartate receptor glycine co-agonist site** refers to a specific ligand-binding domain located on the GluN1 (NR1) and/or GluN3 subunits of the NMDA-type glutamate receptor, a major class of ionotropic glutamate receptors in the central nervous system[1][2][6]. Activation of the NMDA receptor channel requires both glutamate binding (to GluN2 subunits) and glycine binding (to GluN1 and/or GluN3 subunits) as co-agonists; both are essential for channel opening and subsequent calcium entry[1][3][5][6]. The glycine site is thus a modulatory site, and its occupancy by glycine or D-serine profoundly regulates NMDA receptor function, synaptic signaling, plasticity, and disease processes[4][8]. Numerous therapeutic and tool compounds target the glycine site, either to enhance (agonists/partial agonists) or inhibit (antagonists) receptor activity. The glycine site is a validated drug target in neurological and psychiatric disorders, but its pharmacological manipulation requires careful titration due to risks of neurotoxicity or cognitive side effects[2][9].

Other names

NMDA receptor glycine siteGlycine-binding site of NMDA receptorGluN1 glycine siteNR1 subunit glycine siteGlycine modulatory site

Agonists or co-agonists bind the glycine site to enable opening of the NMDA receptor channel in the presence of glutamate, leading to Ca(^2+) influx and downstream signaling[1][2][3][8]. Antagonists block glycine binding, inhibiting channel activation and reducing excitatory signaling[8].